Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

Sinopharm Group Co. Ltd. (X2S1.F)

Compare
10.50
-0.10
(-0.94%)
At close: April 4 at 8:13:02 AM GMT+2
Loading Chart for X2S1.F
  • Previous Close 10.60
  • Open 10.50
  • Bid 9.90 x --
  • Ask 10.60 x --
  • Day's Range 10.50 - 10.50
  • 52 Week Range 9.15 - 13.50
  • Volume 20
  • Avg. Volume 0
  • Market Cap (intraday) 6.752B
  • Beta (5Y Monthly) 0.63
  • PE Ratio (TTM) 7.34
  • EPS (TTM) 1.43
  • Earnings Date Apr 24, 2025 - Apr 28, 2025
  • Forward Dividend & Yield 0.55 (5.17%)
  • Ex-Dividend Date Jun 18, 2024
  • 1y Target Est --

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology, investment, goods and technology import and export, business consulting, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

www.sinopharmgroup.com.cn

108,217

Full Time Employees

December 31

Fiscal Year Ends

Recent News: X2S1.F

View More

Performance Overview: X2S1.F

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

X2S1.F
21.05%
HANG SENG INDEX (^HSI)
13.91%

1-Year Return

X2S1.F
7.10%
HANG SENG INDEX (^HSI)
36.62%

3-Year Return

X2S1.F
23.91%
HANG SENG INDEX (^HSI)
1.54%

5-Year Return

X2S1.F
11.11%
HANG SENG INDEX (^HSI)
1.66%

Compare To: X2S1.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: X2S1.F

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    6.82B

  • Enterprise Value

    9.60B

  • Trailing P/E

    7.44

  • Forward P/E

    7.50

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.09

  • Price/Book (mrq)

    0.66

  • Enterprise Value/Revenue

    0.13

  • Enterprise Value/EBITDA

    4.55

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.21%

  • Return on Assets (ttm)

    2.87%

  • Return on Equity (ttm)

    8.44%

  • Revenue (ttm)

    584.51B

  • Net Income Avi to Common (ttm)

    7.05B

  • Diluted EPS (ttm)

    1.43

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    54.31B

  • Total Debt/Equity (mrq)

    60.29%

  • Levered Free Cash Flow (ttm)

    -10.81B

Research Analysis: X2S1.F

View More

Company Insights: X2S1.F

Research Reports: X2S1.F

View More

People Also Watch